公开(公告)号：US20240156790A1

公开(公告)日：2024-05-16

申请号：US18518731

申请日：2023-11-24

申请人： THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK

发明人： Brent R. STOCKWELL ,  Arie ZASK ,  Hui TAN ,  Jacob D. DANIELS

IPC分类号： A61K31/4245 ,  A61K31/166 ,  A61K31/245 ,  A61K31/421 ,  A61K31/44 ,  A61K31/4439 ,  A61K31/5375 ,  A61P31/06 ,  A61P39/06 ,  C07C229/60 ,  C07C233/65 ,  C07D213/74 ,  C07D213/80 ,  C07D263/32 ,  C07D271/10 ,  C07D295/13 ,  C07D413/04 ,  C07D413/12

CPC分类号： A61K31/4245 ,  A61K31/166 ,  A61K31/245 ,  A61K31/421 ,  A61K31/44 ,  A61K31/4439 ,  A61K31/5375 ,  A61P31/06 ,  A61P39/06 ,  C07C229/60 ,  C07C233/65 ,  C07D213/74 ,  C07D213/80 ,  C07D263/32 ,  C07D271/10 ,  C07D295/13 ,  C07D413/04 ,  C07D413/12

摘要： The present disclosure provides, inter alia, a compound having the structure:




Also provided are compositions containing a pharmaceutically acceptable carrier and one or more compounds according to the present disclosure. Further provided are methods for treating or ameliorating the effects of an excitotoxic disorder in a subject, methods of modulating ferroptosis in a subject, methods of reducing reactive oxygen species (ROS) in a cell, methods for treating or ameliorating the effects of a neurodegenerative disease, methods for alleviating side effects in a subject undergoing radiotherapy and/or immunotherapy, and methods for treating or ameliorating the effects of an infection associated with ferroptosis in a subject.

公开(公告)号：US20230167058A1

公开(公告)日：2023-06-01

申请号：US17931341

申请日：2022-09-12

申请人： THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK

发明人： Brent R. STOCKWELL ,  Hengrui LIU ,  Farhad FOROUHAR ,  Qian WANG

IPC分类号： C07D209/48 ,  A61P35/00 ,  C07D295/16 ,  C07D487/04 ,  C07F7/22 ,  C07D409/04 ,  C07D277/42 ,  C07D403/06 ,  C07D455/02

CPC分类号： C07D209/48 ,  A61P35/00 ,  C07D295/16 ,  C07D487/04 ,  C07F7/2224 ,  C07D409/04 ,  C07D277/42 ,  C07D403/06 ,  C07D455/02

摘要： The present disclosure provides, inter alia, compounds to modulate GPX4 activity. Also provided are pharmaceutical compositions containing same compounds. Further provided are methods for treating or ameliorating the effects of a cancer in a subject, methods of modulating GPX activity in a subject, methods of inducing ferroptosis in a cell, and methods for treating or ameliorating the effects of a cancer in a subject using the compounds or composition in combination with other therapeutic agents.

公开(公告)号：US20230140200A1

公开(公告)日：2023-05-04

申请号：US17818807

申请日：2022-08-10

申请人： THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK

发明人： Brent R. STOCKWELL ,  Angie Huizhong FENG ,  Jenny JIN

IPC分类号： C07K16/28 ,  G01N33/50

摘要： The present disclosure provides, inter alia, methods for identifying cells undergoing non-apoptotic cell death, e.g., ferroptosis, in a subject, using anti-TfR1 antibodies such as 3F3-FMA. Methods for treating or ameliorating the effects of a cancer in a subject, methods for enhancing the anti-tumor effect of radiation in a subject with cancer undergoing radiotherapy, and compositions and kits comprising anti-TfR1 antibodies disclosed herein are also provided. The present disclosure also provides methods for identifying a classifier that detects and classifies a cell death modality in a cell. The classifier constructed by such methods serves as an unbiased tool for identification of features that best distinguish various cell death modalities. Also provided are methods for detecting a cell death modality in a system such as e.g., a cancer patient receiving therapies.

公开(公告)号：US20220412989A1

公开(公告)日：2022-12-29

申请号：US17817601

申请日：2022-08-04

申请人： THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK

发明人： Brent R. STOCKWELL ,  Angie Huizhong FENG

IPC分类号： G01N33/68 ,  G01N33/574 ,  C07K16/28 ,  A61P35/00

摘要： The present disclosure provides, inter alia, methods for identifying cells undergoing non-apoptotic cell death, e.g., ferroptosis, in a subject, using anti-TfR1 antibodies such as 3F3-FMA. Methods for treating or ameliorating the effects of a cancer in a subject, methods for enhancing the anti-tumor effect of radiation in a subject with cancer undergoing radiotherapy, and compositions and kits comprising anti-TfR1 antibodies disclosed herein are also provided.